Litigation Details for Relypsa, Inc. v. Alkem Laboratories Ltd. (D. Del. 2020)
✉ Email this page to a colleague
Relypsa, Inc. v. Alkem Laboratories Ltd. (D. Del. 2020)
Docket | ⤷ Try a Trial | Date Filed | 2020-01-22 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
Jury Demand | Referred To | ||
Patents | 8,147,873; 8,337,824; 9,492,476; 9,925,212 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Relypsa, Inc. v. Alkem Laboratories Ltd.
Details for Relypsa, Inc. v. Alkem Laboratories Ltd. (D. Del. 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2021-07-20 | 90 | Order - -Memorandum and Order | terms of U.S. Patent Nos. 8,147,873 (“the ’873 Patent”), 8,337,824 (“the ’824 Patent”), 9,492,476 (“…four patents, but only one term in one of those patents, U.S. Patent No. 8,147,873, is …(“the ’476 Patent”) and 9,925,212 (“the ’212 Patent”) with agreed-upon constructions are construed as… exchange cations” (’476 Patent, claim 1; ’212 Patent, claim 1) Further, as announced… the entire patent.” Id. at 1321 (internal quotation marks omitted). The patent specification | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |